Opdualag Approved for Unresectable, Metastatic Melanoma
Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody.
Melanoma
Does Aspirin Reduce the Risk of Invasive Melanoma in Older Adults?
Results from a randomized trial neither support nor rule out the possibility that aspirin might have a chemopreventive effect on melanoma incidence.
Lymph Node Dissection Declining in SLN-Positive Melanoma
From 2017 to 2019, increase seen in use of adjuvant systemic therapy, with variation in use among treating centers
Pandemic-Related Decreases in Cancer Detection Persist for Some Cancers
The largest declines in incidence were seen for cervical, endocrine, and prostate cancers, as well as melanoma.
High-Fiber Diet May Benefit Melanoma Patients on Immunotherapy
Higher intake of dietary fiber linked to longer progression-free survival in melanoma patients on immune checkpoint blockade
Risk of Leptomeningeal Metastasis in Melanoma Linked to Anatomic, Surgical Factors
Researchers found that entry into the ventricle space during surgical resection elevated the risk of leptomeningeal disease in patients with melanoma brain metastases.
Experts Disagree on Treatment for Asymptomatic Melanoma Brain Metastasis
Medical and clinical oncologists were more likely than neurosurgeons and radiation oncologists to recommend systemic therapy alone.
FDA-Approved Melanoma Treatments
FDA-approved drug therapies for cutaneous melanoma.
Dermatological Reactions to Anti-Glaucoma Eye Drops
A review of dermatological adverse events associated with anti-glaucoma eye drop is provided.
Relatlimab-Nivolumab Ups PFS in Untreated Advanced Melanoma
Combination provides greater benefit than nivolumab alone for progression-free survival in untreated metastatic or unresectable melanoma
- Loading...
Loading...
Next post in Skin Cancer
Loading... 
Loading...